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Abstract

Opioids and traditional adjuvant medications are frequently prescribed for the management of moderate to
severe cancer pain with good effect. However, there are many cases, in which patients experience severe opioid
refractory cancer pain. Ketamine is being used more frequently in the hospice and palliative setting to manage
opioid refractory pain, although high-quality evidence regarding its effectiveness is lacking. It seems certain
patients respond favorably to ketamine, while others experience no effect. Studies have not yet identified factors
associated with a favorable response to ketamine. We present a case describing the successful treatment of highdose opioid refractory cancer pain with a subanesthetic ketamine infusion and propose the novel use of a preinfusion test bolus of ketamine to identify patients who are likely to respond favorably to an infusion.
Keywords: ketamine; opioid refractory cancer pain; test bolus

line receptors, voltage-gated calcium channels, D2 dopamine
receptors, and GABA receptors. In subanesthetic doses of
ketamine, the patient remains awake and responsive while experiencing significant analgesia. The intravenous (IV) onset
of action is within seconds, and the half-life is *45 minutes.
Side effects of ketamine include dysphoria, misperceptions,
hallucinations, and dissociation. Subanesthetic doses are
commonly associated with mild and transient impairments
in attention, memory, and judgment, which can generally be
controlled by low doses of benzodiazepines or haloperidol.11
Despite its analgesic potential, there remains a paucity
of randomized clinical trials demonstrating the efficacy of
ketamine for severe, opioid-refractory pain. Existing studies
have provided mixed results regarding analgesic benefit of
ketamine for patients with cancer-related pain.12–26 The most
recent Cochrane review for ketamine use as an adjuvant to
opioids in the relief of refractory cancer pain concluded that
there was insufficient evidence to assess benefits and harms
and that more randomized controlled trials examining specific low-dose ketamine clinical regimens are needed.26 Many
case reports support the use of ketamine for this indication.27
However, few formal studies have been done, and results
from existing studies are mixed. One notable negative study
by Hardy et al. examined a rapid ketamine dose escalation
to a dose higher than what has been investigated in most
studies and showed a sizable placebo effect and low number

Introduction

P

ain is a common complication for patients with advanced cancer, occurring in up to 90% of patients.1
Cancer-related pain is often of mixed etiology and may have
nociceptive, neuropathic, and inflammatory components.
Opioids and traditional adjuvant medications are frequently
prescribed for the management of moderate to severe cancer
pain; however, these interventions provide insufficient relief
in some cases.
Opioid-refractory cancer pain is thought to be related to
the activation of N-methyl-d-aspartate (NMDA) receptors in
certain regions of the central nervous system.1 Nociceptive
activation of the NMDA receptor is associated with clinical hyperalgesia, allodynia, and reduced opioid sensitivity.1
Growing evidence suggests that the NMDA receptor plays
an active role in the development of opioid tolerance.2–10
Ketamine is a potent NMDA receptor antagonist. By
blocking activated NMDA receptor channels, it is thought
that ketamine ‘‘resets’’ neuronal hyperexcitability and subsequently reduces pain signaling, thus reducing opioid tolerance. Ketamine is not only 10-fold stronger than methadone
as an NMDA receptor antagonist but also exerts its analgesic effects through many other non-NMDA-binding sites
throughout the central nervous system thought to be involved in pain perception: muscarinic and nicotinic acetylcho-
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needed to harm for adverse side effects.28 The heterogeneous
results may be attributed to small sample sizes, differing
doses, and routes of ketamine administration.
Given the heterogeneity in the literature, it is reasonable to
postulate that there are subgroups of patients who respond to
ketamine and others who do not. Or, perhaps there are certain
cancer pain syndromes that are more or less amenable to
ketamine. We are not aware of any studies that have identified patient factors or characteristics associated with favorable response to ketamine. The ability to identify patients
who are more likely to have a favorable response would allow
clinicians to more rapidly achieve pain control in responders and avoid risk of side effects in nonresponders.
We present the case of a patient with opioid refractory
cancer pain who was treated with a test bolus of low-dose
ketamine before initiating a subanesthetic ketamine infusion.
The test bolus dose used for this patient was derived from the
Henry Ford Policy: Utilization of Low-Dose Ketamine for
Pain Management in Emergency Medicine for Adults (age
older than or equal to 15 years).29 The policy recommends an
IV ketamine bolus range of 0.1 to 0.3 mg/kg (max 30 mg) as
an adjunct analgesic for patients who are tolerant to opioids
or as an alternative to opioids in other acute and chronic pain
diagnoses, including tumor progression, bone metastases,
spinal or orthopedic surgery, major limb injuries, sickle cell
disease, cluster headaches, and chronic abdominal pain.29
As this patient experienced pain relief with the bolus dose,
we felt that he would benefit from initiation of a continuous
infusion of subanesthetic ketamine. We believe that this case
highlights a potential means of identifying patients who are
more likely to benefit from subanesthetic ketamine infusions
for opioid refractory cancer pain.
Case Description

A 32-year-old man receiving home-hospice care with
stage IV gastric adenocarcinoma presented to the emergency
department (ED) in a pain crisis with agitation, confusion,
and drowsiness. The patient suffered from chronic abdominal pain related to his known cancer burden throughout the
small bowel and omentum that had been well-controlled
since his initial enrollment with hospice 8 weeks before presentation with a fentanyl citrate patient-controlled analgesia
(PCA) at home. His wife reported 1–2 weeks of progressive
abdominal pain despite adjustments to his PCA to the settings on presentation of 650-mcg/h continuous infusion and a
200-mcg demand dose with a 10-minute lockout.
Upon interrogation of his pump on presentation, it was
discovered that his fentanyl use had escalated over the preceding days with 18,400 mcg of fentanyl citrate, or 3066 oral
morphine equivalents (OME) two days before presentation,
and with 31,600 mcg of fentanyl citrate, or 5266 OME, in
the 24 hours leading up to presentation. Of note, his wife also
reported administering lorazepam sublingual 1 mg and haloperidol of unknown dose and frequency at home for at least
two days before presentation in an attempt to alleviate his
pain and agitation without effect.
On examination, the patient was described as restless,
disoriented to the situation, and unable to appropriately answer questions. His abdomen was described as nondistended,
diffusely tender to palpation, with bowel sounds present.
There was notably no mention of myoclonus or seizure-like
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activity that may have raised concern for opioid-induced
neurotoxicity. In the ED, his fentanyl PCA was maintained
with registered nurse (RN) as-needed boluses in the setting
of his altered mentation, and he was given hydromorphone
hydrochloride IV 6 mg and dexamethasone IV 10 mg without
effect in his pain.
One hour and 21 minutes after he received the IV hydromorphone, he was given a 0.3 mg/kg ketamine hydrochloride
bolus with improvement noted in his pain. This was chosen
as the bolus dose as opposed to a lower dose due to the
severity of the patient’s pain and his younger age. IV methadone could also have been considered here as an alternative
to the ketamine bolus, although this was not available on our
hospital formulary at the time.
Success of the ketamine bolus was determined based
on both his documented Pain Assessment in Advanced
Dementia Scale (PAINAD) scores from a maximum score of
10 before his ketamine bolus, to a score of 7 approximately
four hours after the ketamine bolus (PAINAD scores had
remained 10 after administration of the hydromorphone and
dexamethasone), as well as subjective data from both the
patient’s wife stating ‘‘patient improved most following
the ketamine bolus,’’ and bedside RN documentation noting that ‘‘Patient does appear to be less symptomatic’’ following the ketamine bolus. The PAINAD scale was initially
utilized given his encephalopathy on presentation. Of note,
the patient received a single dose of haloperidol IV 2 mg for
agitation on the evening of admission, approximately seven
hours after he received the initial ketamine bolus. He did not
receive any additional haloperidol throughout the rest of his
hospitalization.
He was subsequently admitted to the inpatient hospice unit
for further pain management. He was then initiated on a lowdose ketamine hydrochloride infusion at 0.1 mg/kg/h and
was rotated to a hydromorphone hydrochloride PCA at a continuous infusion of 13 mg/h (a 25% dose reduction from total
fentanyl use) and a 10 mg demand dose with a 10-minute
lockout. Upon reassessment later in the evening on the day
of admission, the patient appeared uncomfortable; thus, his
ketamine infusion was titrated upward to 0.2 mg/kg/h with
improvement of his pain.
By the following morning, the patient was alert and participating in conversations, and was able to ‘‘state his pain
was ‘okay’ and that he did not need an additional as needed
dose at this time.’’ His wife reported to the hospice team
that the patient slept well overnight for the first time in two
years. He was maintained at this ketamine infusion rate
with adequate pain control while his hydromorphone PCA
was tapered down over a period of 4 days to a continuous
infusion of 6 mg/h and demand dose of 8 mg with a 10-minute
lockout.
Of note, the patient experienced restlessness and impulsiveness throughout his hospital course, which were initially
treated with lorazepam 1 mg IV every eight hours scheduled
plus 2 mg IV every two hours, as needed. Approximately
halfway through his hospital course, this was adjusted to
his discharge regimen of lorazepam 1 mg IV every morning, 1 mg IV every afternoon, and 2 mg IV nightly. He also
experienced mild nondisturbing hallucinations and vivid
dreams that did not require any additional treatment.
He was subsequently weaned off the ketamine infusion
6 days after admission with sustained pain control and a 50%
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decrease in his opioid requirement, from 5266 OME on
presentation to 2600 OME before discharge (Fig. 1). The
patient discharged home with adequate pain control on the
hydromorphone PCA with home hospice care. His pain control was reportedly maintained until his death 13 days after
discharge.
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Discussion

Our case supports the utility of subanesthetic ketamine for
opioid refractory cancer pain. In addition, it highlights a preinfusion subanesthetic ketamine bolus as a potential method
of identifying patients who are likely to respond favorably
to a subanesthetic ketamine infusion. IV ketamine’s onset of
action is within seconds with a half-life in the 45-minute
range. These properties allow a bolus to quickly identify response to ketamine, and for patients who respond, it provides
long enough relief to bridge until the subanesthetic infusion
is available.
This patient appeared to respond favorably to ketamine
with regard to pain with minimal adverse effects. The patient
and his wife did report occasional hallucinations that were
possibly related to the ketamine infusion versus high-dose
opioids that were eventually decreased, although these hallucinations were nondisturbing and gradually improved.
He initially presented encephalopathic and disoriented and
was unable to participate in questioning. By the following
morning, <24 hours after the initial ketamine bolus, he was
alert and answering questions appropriately. The timing of
the resolution of his encephalopathy appeared to correlate
with improvement in his pain.
It should be noted and considered that this patient’s pain
crisis was purely the result of opioid hyperalgesia given the
high doses used and rapid escalation in the days leading up
to his inpatient admission. An argument can be made that
the improvement in his pain is explained by opioid rotation
and dose reduction alone. In this case, however; we feel the
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patient’s improvement in pain is better explained by ketamine given the initial favorable response after ketamine bolus
which was administered before an opioid rotation.
Another major point of consideration is the use of possible confounding adjunctive medications in the treatment of
this patient’s pain. The concept of total pain involves addressing not only a patient’s physical pain, but also their
psychological, spiritual, and social needs. Benzodiazepines
and antipsychotics are frequently utilized in palliative and
hospice care for the treatment of symptoms relating to a patient’s emotional or psychological state if felt to be contributing to their total pain. This patient was receiving lorazepam
and haloperidol of unknown amounts for at least two days
before this presentation, and while he only received one
dose of haloperidol for agitation after presentation, he was
consistently given scheduled IV lorazepam throughout his
hospitalization for ongoing restlessness and impulsiveness,
which certainly could have resulted in improvement in his
total pain if a psychological aspect was contributing.
However, we do feel that the majority of his pain was truly
physical in relationship to his known cancer burden, as it is
worth noting that he had never expressed any prior issues
with emotional or spiritual distress during his outpatient visits
to the palliative care office in the few months preceding his
death, although this could have changed as he entered the
final days and weeks of life.
In conclusion, we hypothesize that a subanesthetic ketamine bolus can be used as a method to identify patients with
opioid refractory cancer pain who are likely to benefit from
a subanesthetic ketamine continuous infusion. Our case offers one example of the successful implementation of this
approach, although future studies are needed to better investigate the effectiveness of a preinfusion ketamine bolus.
Although ideal, a blinded randomized controlled trial would
likely not be feasible due to ethical issues pertaining to the
care of patients at the end of life. Alternatively, case control
studies involving patients with opioid refractory cancer pain

FIG. 1. Total opioid requirements (converted to OME) throughout the patient’s hospitalization, pre- and postketamine
administration. OME, oral morphine equivalents.
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may be a good option. We recommend inclusion criteria as
patients with cancer pain uncontrolled with opioids with and
without adjunctive medications.
It would be helpful if all adjuncts were already at what is
considered to be a therapeutic dose and duration before initiating ketamine to avoid a possible confounder of the adjunct
simply not yet reaching therapeutic potential. We recommend exclusion criteria as patients with contraindications
to ketamine, such as those with schizophrenia or other psychoses, or dementia, due to the possibility of the adverse
effect of vivid dreams/hallucinations causing increased agitation in these populations. This case adds important data to
the evidence base for subanesthetic ketamine for opioid refractory cancer pain and offers direction for future studies.
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